PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
PTCT - PTC Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$98.00
DETAILS
HIGH:
$120.00
LOW:
$82.00
MEDIAN:
$94.00
CONSENSUS:
$98.00
UPSIDE:
42.42%
Stock News
PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage
PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model, anchored by the successful Sephience launch. Sephience's rapid commercial uptake is offsetting DMD franchise declines, with Q1 2026 product revenue up 47% year-over-year and strong patient onboarding momentum. PTCT's partnership with Novartis on votoplam for Huntington's disease offers de-risked late-stage upside, while a $1.9B cash position provides strategic flexibility and reduces near-term dilution risk.
PTC Therapeutics Q1 Earnings Call Highlights
PTC Therapeutics NASDAQ: PTCT reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or PKU.
PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript
PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $10.04 per share a year ago.
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise – – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth – – Positive topline results from 24-month interim analysis of PIVOT-HD extension study of votoplam, supporting ongoing global Phase 3 INVEST-HD study and potential regulatory interactions – – Open-label vatiquinone registration study to be initiated in Q3 2026 based on FDA feedback – WARREN, N.J., May 7, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2026.
Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for PTC Therapeutics (PTCT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.
PTC Therapeutics to Participate in Upcoming Investor Conferences
WARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities Health Care Conference 2026 Tuesday, May 12 at 8:40 a.m.
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's Disease Transcript
PTC Therapeutics, Inc. (PTCT) Discusses 24-Month Interim Results of PIVOT-HD Long-Term Extension Study of Votoplam in Huntington's Disease Transcript
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers
PTC Therapeutics Inc. (NASDAQ:PTCT) shares are tumbling on Wednesday, after the company reported topline results from the 24-month interim analysis of its PIVOT-HD long-term extension study.
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile - - Novartis initiated global Phase 3 INVEST-HD study of votoplam - - PTC will host a conference call to discuss results today, April 28, at 4:30 pm ET - WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to an external natural history cohort.
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m.
Abacus FCF Advisors LLC Makes New $5.76 Million Investment in PTC Therapeutics, Inc. $PTCT
Abacus FCF Advisors LLC bought a new stake in PTC Therapeutics, Inc. (NASDAQ: PTCT) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 75,757 shares of the biopharmaceutical company's stock, valued at approximately $5,755,000. Abacus FCF Advisors LLC owned about 0.09% of
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
WARREN, N.J., April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, May 7, 2026, at 4:30 p.m.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of 1,155 shares of its common stock and 925 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee.
Burney Co. Takes Position in PTC Therapeutics, Inc. $PTCT
Burney Co. bought a new stake in PTC Therapeutics, Inc. (NASDAQ: PTCT) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 26,569 shares of the biopharmaceutical company's stock, valued at approximately $2,018,000. Several other institutional investors and hedge funds have also
PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden Sells 829 Shares
PTC Therapeutics, Inc. (NASDAQ: PTCT - Get Free Report) EVP Lee Scott Golden sold 829 shares of PTC Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $67.99, for a total value of $56,363.71. Following the completion of the sale, the executive vice president directly
Phocas Financial Corp. Has $1.94 Million Stock Position in PTC Therapeutics, Inc. $PTCT
Phocas Financial Corp. lessened its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 31.6% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,482 shares of the biopharmaceutical company's stock after selling 11,752 shares during the period. Phocas Financial Corp.'s holdings in PTC
Price Targets
PTC Therapeutics price target raised to $94 from $92 at Morgan Stanley
$94.00
(was $75.36)
Judah Frommer
·
Morgan Stanley
PTC Therapeutics initiated with an Outperform at Raymond James
$108.00
(was $69.11)
Tiago Fauth
·
Raymond James
PTC Therapeutics price target raised to $92 from $90 at Morgan Stanley
$92.00
(was $70.66)
Morgan Stanley
PTC Therapeutics price target raised to $120 from $119 at Barclays
$120.00
(was $70.66)
Eliana Merle
·
Barclays
PTC Therapeutics price target raised to $82 from $78 at RBC Capital
$82.00
(was $67.94)
Brian Abrahams
·
RBC Capital
PTC Therapeutics price target lowered to $86 from $93 at Wells Fargo
$86.00
(was $69.90)
Wells Fargo
PTC Therapeutics assumed with Overweight from Equal Weight at Barclays
$119.00
(was $75.49)
Barclays
PTC Therapeutics price target raised to $90 from $78 at Morgan Stanley
$90.00
(was $77.24)
Morgan Stanley
PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
$91.00
(was $85.99)
RBC Capital
PTC Therapeutics price target raised to $50 from $44 at Goldman Sachs
$50.00
(was $71.79)
Goldman Sachs
PTC Therapeutics price target raised to $93 from $73 at Wells Fargo
$93.00
(was $67.72)
Tiago Fauth
·
Wells Fargo
PTC Therapeutics price target raised to $68 from $46 at Barclays
$68.00
(was $67.72)
Gena Wang
·
Barclays
PTC Therapeutics price target raised to $77 from $63 at Jefferies
$77.00
(was $67.86)
Kelly Shi
·
Jefferies
PTC Therapeutics price target lowered to $70 from $72 at Baird
$70.00
(was $45.38)
Joel Beatty
·
Robert W. Baird
PTC Therapeutics price target lowered to $66 from $70 at Baird
$66.00
(was $36.19)
Joel Beatty
·
Robert W. Baird
PTC Therapeutics price target lowered to $58 from $63 at RBC Capital
$58.00
(was $44.61)
Brian Abrahams
·
RBC Capital
PTC Therapeutics (PTCT) PT Raised to $52 at Baird
$52.00
(was $45.09)
Joel Beatty
·
Robert W. Baird
PTC Therapeutics price target raised to $45 from $32 at Morgan Stanley
$45.00
(was $38.48)
Jeffrey Hung
·
Morgan Stanley
UBS Upgrades PTC Therapeutics (PTCT) to Buy
$47.00
(was $34.99)
Colin Bristow
·
UBS
PTC Therapeutics price target raised to $32 from $30 at Morgan Stanley
$32.00
(was $33.20)
Jeffrey Hung
·
Morgan Stanley